Comparison Between Prone SPECT-Based Semi-Quantitative Parameters and MBI-Based Semi-Quantitative Parameters in Patients with Locally Advanced Breast Cancer.

IF 3 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Molecular Imaging and Biology Pub Date : 2024-11-08 DOI:10.1007/s11307-024-01959-1

Alina van de Burgt, Floris H P van Velden, Christinne L S Corion, Angela Collarino, Renato A Valdés Olmos, Frits Smit, Lioe-Fee de Geus-Oei, Lenka M Pereira Arias-Bouda

{"title":"Comparison Between Prone SPECT-Based Semi-Quantitative Parameters and MBI-Based Semi-Quantitative Parameters in Patients with Locally Advanced Breast Cancer.","authors":"Alina van de Burgt, Floris H P van Velden, Christinne L S Corion, Angela Collarino, Renato A Valdés Olmos, Frits Smit, Lioe-Fee de Geus-Oei, Lenka M Pereira Arias-Bouda","doi":"10.1007/s11307-024-01959-1","DOIUrl":null,"url":null,"abstract":"Purpose: This study evaluates the semi-quantitative single-photon emission computed tomography (SPECT) parameters of prone SPECT using [99mTc]Tc-sestamibi and compares them with Molecular Breast Imaging (MBI)-derived semi-quantitative parameters for the potential use of response prediction in women with locally advanced breast cancer (LABC).Procedures: Patients with proven LABC with a tumor ≥ 2 cm on mammography and an indication for MBI using [99mTc]Tc-sestamibi were prospectively enrolled. All patients underwent a prone SPECT/CT at 5 min (early exam) and an additional scan at 90 min (delayed exam) after injection of 600 MBq [99mTc]Tc-sestamibi to compose wash-out rates (WOR). All patients underwent MBI after early SPECT/CT. Volumes of interest of the primary tumor were drawn semi-automatically on early and delayed SPECT images. Semi-quantitative analysis included maximum and mean standardized uptake values (SUVmax, SUVmean,), functional tumor volume (FTVSPECT), total lesion mitochondrial uptake (TLMU), tumor-to-background ratios (TBRmax and TBRmean), WOR and coefficient of variation (COVSPECT). Subsequently, the FTVSPECT, TBRSPECT and COVSPECT were compared to FTVMBI, TBRMBI and COVMBI.Results: Eighteen patients were included. Early SUVmax, and TBRmax showed significantly higher interquartile range (IQR) compared to SUVmean and TBRmean, respectively 2.22 (2.33) g/mL, 6.86 (8.69), 1.29 (1.39) g/mL and 3.99 (5.07) (median (IQR), p < 0.05). WOR showed a large IQR (62.28), indicating that there is WOR variation among the LABC patients. FTV showed no difference between MBI and early SPECT semi-quantitative parameter (p = 0.46).Conclusions: In LABC patients it is feasible to obtain semi-quantitative parameters from prone SPECT/CT. The FTV derived from early prone SPECT/CT is comparable with MBI-based FTV. Studies with comprehensive clinical parameters are needed to establish the clinical relevance of these semi-quantitative parameters, including WOR, for response prediction before its use in clinical routine.","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11307-024-01959-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study evaluates the semi-quantitative single-photon emission computed tomography (SPECT) parameters of prone SPECT using [^99mTc]Tc-sestamibi and compares them with Molecular Breast Imaging (MBI)-derived semi-quantitative parameters for the potential use of response prediction in women with locally advanced breast cancer (LABC).

Procedures: Patients with proven LABC with a tumor ≥ 2 cm on mammography and an indication for MBI using [^99mTc]Tc-sestamibi were prospectively enrolled. All patients underwent a prone SPECT/CT at 5 min (early exam) and an additional scan at 90 min (delayed exam) after injection of 600 MBq [^99mTc]Tc-sestamibi to compose wash-out rates (WOR). All patients underwent MBI after early SPECT/CT. Volumes of interest of the primary tumor were drawn semi-automatically on early and delayed SPECT images. Semi-quantitative analysis included maximum and mean standardized uptake values (SUV_max, SUV_mean,), functional tumor volume (FTV_SPECT), total lesion mitochondrial uptake (TLMU), tumor-to-background ratios (TBR_maxand TBR_mean), WOR and coefficient of variation (COV_SPECT). Subsequently, the FTV_SPECT, TBR_SPECT and COV_SPECT were compared to FTV_MBI, TBR_MBI and COV_MBI.

Results: Eighteen patients were included. Early SUV_max, and TBR_max showed significantly higher interquartile range (IQR) compared to SUV_mean and TBR_mean, respectively 2.22 (2.33) g/mL, 6.86 (8.69), 1.29 (1.39) g/mL and 3.99 (5.07) (median (IQR), p < 0.05). WOR showed a large IQR (62.28), indicating that there is WOR variation among the LABC patients. FTV showed no difference between MBI and early SPECT semi-quantitative parameter (p = 0.46).

Conclusions: In LABC patients it is feasible to obtain semi-quantitative parameters from prone SPECT/CT. The FTV derived from early prone SPECT/CT is comparable with MBI-based FTV. Studies with comprehensive clinical parameters are needed to establish the clinical relevance of these semi-quantitative parameters, including WOR, for response prediction before its use in clinical routine.

查看原文本刊更多论文

局部晚期乳腺癌患者基于俯卧位 SPECT 的半定量参数与基于 MBI 的半定量参数的比较

目的：本研究评估了使用[99m锝]锝-sestamibi的俯卧位SPECT的半定量单光子发射计算机断层扫描（SPECT）参数，并将其与分子乳腺成像（MBI）得出的半定量参数进行比较，以用于局部晚期乳腺癌（LABC）女性患者的潜在反应预测：程序：前瞻性地招募了经证实患有局部晚期乳腺癌（LABC）且乳房X光检查显示肿瘤≥2厘米、有使用[99m锝]锝-铯-γ-同位素进行MBI检查指征的患者。所有患者都在注射 600 MBq [99mTc]Tc-sestamibi 后 5 分钟（早期检查）接受了俯卧 SPECT/CT，并在 90 分钟（延迟检查）接受了额外扫描，以计算洗脱率（WOR）。所有患者在早期SPECT/CT检查后都接受了MBI检查。在早期和延迟 SPECT 图像上半自动绘制原发肿瘤的感兴趣容积。半定量分析包括最大和平均标准化摄取值（SUVmax、SUVmean）、功能性肿瘤体积（FTVSPECT）、病变线粒体总摄取量（TLMU）、肿瘤与背景比率（TBRmax 和 TBRmean）、WOR 和变异系数（COVSPECT）。随后，将 FTVSPECT、TBRSPECT 和 COVSPECT 与 FTVMBI、TBRMBI 和 COVMBI 进行比较：结果：共纳入 18 名患者。与 SUVmean 和 TBRmean 相比，早期 SUVmax 和 TBRmax 的四分位数间距 (IQR) 明显更高，分别为 2.22 (2.33) g/mL、6.86 (8.69)、1.29 (1.39) g/mL 和 3.99 (5.07)（中位数 (IQR)，P 结论：在LABC患者中，通过俯卧位SPECT/CT获得半定量参数是可行的。早期俯卧位 SPECT/CT 得出的 FTV 与基于 MBI 的 FTV 相当。在将这些半定量参数（包括 WOR）用于临床常规反应预测之前，需要对其进行全面的临床参数研究，以确定其临床相关性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Imaging and Biology 医学-核医学

CiteScore

6.90

自引率

3.20%

发文量

审稿时长

3 months

期刊介绍： Molecular Imaging and Biology (MIB) invites original contributions (research articles, review articles, commentaries, etc.) on the utilization of molecular imaging (i.e., nuclear imaging, optical imaging, autoradiography and pathology, MRI, MPI, ultrasound imaging, radiomics/genomics etc.) to investigate questions related to biology and health. The objective of MIB is to provide a forum to the discovery of molecular mechanisms of disease through the use of imaging techniques. We aim to investigate the biological nature of disease in patients and establish new molecular imaging diagnostic and therapy procedures. Some areas that are covered are: Preclinical and clinical imaging of macromolecular targets (e.g., genes, receptors, enzymes) involved in significant biological processes. The design, characterization, and study of new molecular imaging probes and contrast agents for the functional interrogation of macromolecular targets. Development and evaluation of imaging systems including instrumentation, image reconstruction algorithms, image analysis, and display. Development of molecular assay approaches leading to quantification of the biological information obtained in molecular imaging. Study of in vivo animal models of disease for the development of new molecular diagnostics and therapeutics. Extension of in vitro and in vivo discoveries using disease models, into well designed clinical research investigations. Clinical molecular imaging involving clinical investigations, clinical trials and medical management or cost-effectiveness studies.